Palantir Q4: Sell Now To Avoid Pain Later (Rating Downgrade)
Palantir’s Q4 revealed a 45% operating margin and 36% revenue growth, but its shares reflect over five years’ growth already.
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Equinor Unveils $5 Billion Buyback, Trims Renewables Spending As Oil & Gas Output Rises
Equinor (NYSE: EQNR) reports Q4 results with revenue and production decline, but beats EPS estimate. Plans to strengthen cash flow and increase renewable energy capacity.